Back to today’s briefing

Story perspectives

Sanofi to Acquire Blueprint Medicines for $9.5 Billion

6/2/2025

32 4

Summary

Story summary

Sanofi is set to acquire Blueprint Medicines for a staggering $9.5 billion, a move that will significantly bolster its immunology portfolio. This strategic deal includes Ayvakit, the sole approved treatment for systemic mastocytosis, and opens doors to Blueprint's promising early-stage pipeline. Anticipated to finalize in Q3 2025, this acquisition positions Sanofi as a formidable player in the rare disease arena.

1 of 1

Story summary

Sanofi is set to acquire Blueprint Medicines for a staggering $9.5 billion, a move that will significantly bolster its immunology portfolio. This strategic deal includes Ayvakit, the sole approved treatment for systemic mastocytosis, and opens doors to Blueprint's promising early-stage pipeline. Anticipated to finalize in Q3 2025, this acquisition positions Sanofi as a formidable player in the rare disease arena.